Physician profile
Rafael Lastra
NPI 1477550150
$5,079.06
in general payments reported to CMS, 2019-2025
25 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $655 · 2021: $848 · 2022: $607 · 2023: $657 · 2024: $543 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823 · Education: $68.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.75 |
| Education | $68.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pbg Puerto Rico LLC | $828.76 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $790.31 | 2019-2025 | Xarelto, Invokana, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $537.34 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $456.90 | 2019-2024 | Eliquis, Camzyos |
| Amgen INC. | $455.72 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $434.52 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Edwards Lifesciences Corporation | $268.95 | 2021-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $230.90 | 2019-2025 | Winrevair, Verquvo, Janumet |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $189.84 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $185.36 | 2019-2024 | Emblem Mri S-Icd |
| Medtronic, INC. | $125.40 | 2021-2022 | |
| Gilead Sciences, INC. | $116.34 | 2019 | |
| Abbott Laboratories | $69.22 | 2020-2025 | Gallant, Xience Skypoint |
| Medtronic Vascular, INC. | $56.74 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $48.99 | 2025 | Opsumit, Uptravi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer Pharmaceuticals LLC | $48.19 | 2019 | |
| Cordis US Corp. | $44.65 | 2022-2025 | Mynx Control Venous, Zephyr |
| Bayer Puerto Rico INC. | $40.85 | 2025 | Kerendia |
| Pfizer INC. | $27.46 | 2019-2024 | |
| Scpharmaceuticals INC. | $25.00 | 2025 | |
| Biotronik INC. | $24.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.00 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.58 | 2019 | |
| Teleflex LLC | $19.54 | 2019 | |
| Terumo Medical Corporation | $14.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Lastra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.